1. Home
  2. TACT vs OTLK Comparison

TACT vs OTLK Comparison

Compare TACT & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TransAct Technologies Incorporated

TACT

TransAct Technologies Incorporated

HOLD

Current Price

$3.27

Market Cap

37.2M

Sector

Technology

ML Signal

HOLD

Logo Outlook Therapeutics Inc.

OTLK

Outlook Therapeutics Inc.

HOLD

Current Price

$0.34

Market Cap

38.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TACT
OTLK
Founded
1996
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.2M
38.7M
IPO Year
1996
2016

Fundamental Metrics

Financial Performance
Metric
TACT
OTLK
Price
$3.27
$0.34
Analyst Decision
Strong Buy
Buy
Analyst Count
1
4
Target Price
$5.00
$2.50
AVG Volume (30 Days)
57.1K
1.1M
Earning Date
03-10-2026
02-17-2026
Dividend Yield
N/A
N/A
EPS Growth
87.88
55.91
EPS
N/A
N/A
Revenue
N/A
$8,146,123.00
Revenue This Year
$10.36
$1,726.70
Revenue Next Year
N/A
$80.34
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.06
$0.29
52 Week High
$5.70
$3.39

Technical Indicators

Market Signals
Indicator
TACT
OTLK
Relative Strength Index (RSI) 41.20 35.43
Support Level N/A N/A
Resistance Level $3.87 $0.46
Average True Range (ATR) 0.26 0.04
MACD 0.00 0.00
Stochastic Oscillator 31.16 32.66

Price Performance

Historical Comparison
TACT
OTLK

About TACT TransAct Technologies Incorporated

Transact Technologies Inc develops and sells software-driven technology and printing solutions. The company's software is sold under BOHA, AccuDate, Epic, EPICENTRAL, Ithaca, and Printrex brand names. It also provides supplies and consumables used in the printing and scanning activities to restaurant and hospitality, banking, retail, casino and gaming, point of sale automation, lottery, medical, mobile, oil, and gas markets. Majority of the revenue is derived from the casinos and gaming industry followed by the Foodservice technology market. Its geographical segments are the United States and International, of which the majority of its revenue comes from the United States.

About OTLK Outlook Therapeutics Inc.

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.

Share on Social Networks: